RecruitingNot applicableNCT07361874
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Studying NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Texas Southwestern Medical Center
- Intervention
- Intervention 1: Adrenalectomy(procedure)
- Enrollment
- 75 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2030
Study locations (1)
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07361874 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07247058Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)Johns Hopkins University
- RECRUITINGPHASE2NCT07104812Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)Mayo Clinic
- ACTIVE NOT RECRUITINGPHASE2NCT06106295Metyrapone for Mild Autonomous Cortisol Secretion (MACS)Mayo Clinic
See all trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor →